13Feb

[Comment] Pimavanserin for patients with Alzheimer’s disease psychosis

Pimavanserin is an atypical antipsychotic marketed in the USA for hallucinations and delusions associated with Parkinson's disease.1 It acts as an inverse agonist at the 5-HT2A receptor with no effect on dopamine receptors. A boxed warning on the prescribing information approved by the US Food and Drug Administration states that pimavanserin is not approved for elderly patients with dementia-related psychosis unrelated to Parkinson's disease psychosis, and that these patients are at increased risk of death when treated with antipsychotics.

Ander nieuws

20May

[Comment] A new step towards targeting tau

Progressive supranuclear palsy is a rare neurodegenerative disease characterised by an axial parkins...

naar nieuwsitem

20May

[Review] CSF and blood biomarkers for Parkinson’s disease

In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers are urg...

naar nieuwsitem

22Apr

Parkinson’s disease patient: ‘I can walk… it’s really helped me’

Parkinson's disease patient Gail Jardine can walk more freely after having a spinal implant fit...

naar nieuwsitem